Other
Bispecific Antibody
0
Pipeline Programs↗
5
Active Trials↗
4
Companies Involved↗
Bispecific Antibody is an early-stage landscape with 0 programs across 4 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Eli Lilly, BeiGene.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
16
clinical trials
Completed6 · 38%
Terminated2 · 13%
Active, not recruiting2 · 13%
Not yet recruiting2 · 13%
Approved for marketing1 · 6%
Unknown status1 · 6%
Other2 · 13%
Clinical Trials
Trial Activity
16 trials
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Recruiting·—·Phase 2·NCT06822972·27 enrolled
10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults
Active, not recruiting·—·Phase 1·NCT05890963·20 enrolled
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Active, not recruiting·—·Phase 1/2·NCT04868877·194 enrolled
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07407010·10 enrolled
10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults
Completed·—·Phase 1·NCT03875209·54 enrolled
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
Completed·—·Phase 1·NCT03922204·72 enrolled
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
Terminated·—·Phase 1·NCT03927573·23 enrolled
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Approved for marketing·—·N/A·NCT04100694
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)